Gastrointestinal Side Effects are the predominant category of adverse reactions: Nausea affects approximately 12-24% of diabetes patients and up to 30% of weight management patients, typically most severe during the first few weeks of treatment or following dose increases Diarrhea occurs in 13-17% of diabetes patients and up to 24% of weight management patients Vomiting is reported by 6-10% of diabetes patients and up to 12% of weight management patients, particularly at higher doses Constipation affects 6-11% of diabetes patients and up to 17% of weight management patients Dyspepsia and abdominal pain occur in 6-9% of patients Decreased appetite is common and contributes to the medication's weight loss effects Gastroesophageal reflux disease (GERD) occurs in some patients, particularly at higher doses These gastrointestinal symptoms typically diminish over time as the body adapts to the medication
using escalating dosing, as follows: 0.01 mg/kg semaglutide twice weekly for week one, 0.03 mg/kg semaglutide twice weekly for week two and 0.05 mg/kg semaglutide twice weekly for week three (as shown in Fig
This group of medications can either be given by injection or as a once-daily tablet
Combining Wegovy (semaglutide) with other glucose-lowering agents, especially sulfonylureas or insulin, might heighten the risk of hypoglycemia or low blood sugar
Compounding the issue, GLP-1RAs delay gastric emptying, which may reduce the absorption of oral medications, including isotretinoin and oral contraceptivespotentially compromising both acne treatment and pregnancy prevention
These data indicate that GSH-dependent ETC dysfunction mostly affected the activity of CI and CII
